论文部分内容阅读
目的:探讨依达拉奉联合阿替普酶治疗急性脑梗死的临床疗效以及对炎性因子水平的影响。方法:收取2012年5月至2015年5月间我院收治的急性脑梗死患者115例作为研究对象,随机分为观察组及对照组。对照组57例仅给予阿替普酶治疗,观察组58例在对照组的基础上加用依达拉奉。比较两组患者炎性因子水平、神经功能缺损评分、临床疗效以及不良反应发生情况。结果:治疗前,两组患者CRP、IL-6、IL-8及TNF-α等各项炎性因子水平以及NIHSS评分均无显著差异(P>0.05)。两组患者炎性因子水平随治疗进行显著下降,观察组显著低于对照组(P<0.05)。治疗后3个月,观察组患者总有效率(96.55%)显著高于对照组(85.96%),差异有统计学意义(P<0.05)。观察组不良反应发生率(5.17%)与对照组(7.02%)相比无显著差异(P>0.05)。结论:依达拉奉联合阿替普酶可有效降低血清炎症因子水平,治疗急性脑梗死具有良好的临床疗效及安全性,值得临床推广应用。
Objective: To investigate the clinical efficacy of edaravone combined with alteplase in the treatment of acute cerebral infarction and its effect on the level of inflammatory cytokines. Methods: One hundred and fifteen patients with acute cerebral infarction admitted from May 2012 to May 2015 in our hospital were randomly divided into observation group and control group. Control group, 57 cases were given only for alteplase treatment, observation group, 58 cases in the control group based on the addition of edaravone. The levels of inflammatory cytokines, neurological deficit score, clinical efficacy and incidence of adverse reactions in the two groups were compared. Results: Before treatment, the levels of CRP, IL-6, IL-8, TNF-α and other inflammatory factors and NIHSS scores were not significantly different between two groups (P> 0.05). The level of inflammatory cytokines in both groups decreased significantly with the treatment, the observation group was significantly lower than the control group (P <0.05). Three months after treatment, the total effective rate (96.55%) in the observation group was significantly higher than that in the control group (85.96%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group (5.17%) was not significantly different from that in the control group (7.02%) (P> 0.05). Conclusion: Edaravone combined with alteplase can effectively reduce serum levels of inflammatory cytokines and has a good clinical efficacy and safety in the treatment of acute cerebral infarction. It is worthy of clinical application.